Inventor · disambiguated record
Dillon Harding Miles
Also filed as: MILES DILLON · MILES DILLON HARDING
18 granted patents·6 pending applications·80 citations·filing 2017–2024
92Inventor score
Files withARCUS BIOSCIENCES INC24
Top patents by PatentIndex Score
24 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0296US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0395US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 0495US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 0594US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 0692US10399962B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·13 cites·25 claims
- 0791US11819512B2Solid forms of a CD73 inhibitor and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Nov 21, 2023·5 cites·17 claims
- 0888US12195447B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2021·Granted Jan 14, 2025·1 cites·2 claims
- 0987US11072597B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2019·Granted Jul 27, 2021·3 cites·14 claims
- 1086US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 1185US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 1283US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1379US11267845B2Inhibitors of CD73-mediated immunosuppressionARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 8, 2022·1 cites·32 claims
- 1479US11045472B2Quinazoline-pyridine derivatives for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Jun 29, 2021·1 cites·20 claims
- 1578US12195482B1Compounds as inhibitors of AXLARCUS BIOSCIENCES INC·Filed 2024·Granted Jan 14, 2025·0 cites·2 claims
- 1669US2025230173A1Salt forms of an axl inhibitorARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1767US2023416277A1Compounds as inhibitors of axlARCUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 1860US11993584B2Solid forms of an azolopyrimidine compoundARCUS BIOSCIENCES INC·Filed 2019·Granted May 28, 2024·0 cites·21 claims
- 1954US2024226115A1Axl inhibitor compoundsARCUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2053US2024246967A1Axl compoundsARCUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2151US2022235031A1Processes for preparing aminopyrimidine compoundsARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2248US12064433B2Pyridone A2R antagonistsARCUS BIOSCIENCES INC·Filed 2019·Granted Aug 20, 2024·0 cites·25 claims
- 2345US12410170B22,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compoundsARCUS BIOSCIENCES INC·Filed 2020·Granted Sep 9, 2025·0 cites·13 claims
- 2444US11220492B2Quinazoline-pyrazole derivatives for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Jan 11, 2022·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Dillon Harding Miles files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →